Advanced search
Publication Cover
Expert Opinion on Investigational Drugs Volume 28, 2019 - Issue 3
Submit an article Journal homepage
297
Views
11
CrossRef citations to date
0
Altmetric
Drug Evaluation

AQ-13 - an investigational antimalarial drug

Juliana Boex MengueInstitute of Tropical Medicine, University Hospital Tuebingen, Tuebingen, GermanyView further author information
,
Jana HeldInstitute of Tropical Medicine, University Hospital Tuebingen, Tuebingen, GermanyView further author information
&
Andrea KreidenweissInstitute of Tropical Medicine, University Hospital Tuebingen, Tuebingen, Germany;Centre de Recherches Médicales de Lambaréné, Albert Schweitzer Hospital, Lambaréné, GabonCorrespondence[email protected]
View further author information
Pages 217-222 | Received 01 Nov 2018, Accepted 14 Dec 2018, Published online: 05 Jan 2019

  • WHO. World malaria report. Geneva; 2017.
  • WHO. Guidelines for the treatment of malaria. 3rd edn. [Internet]. WHO. [cited 2017 Nov 6]. Available from: http://www.who.int/malaria/publications/atoz/9789241549127/en/
  • Tun KM, Imwong M, Lwin KM, et al. Spread of artemisinin-resistant Plasmodium falciparum in Myanmar: a cross-sectional survey of the K13 molecular marker. Lancet Infect Dis. 2015;15:415–421.
  • Lu F, Culleton R, Zhang M, et al. Emergence of indigenous artemisinin-resistant Plasmodium falciparum in Africa. N Engl J Med. 2017;376:991–993.
  • Artemisinin-resistant Plasmodium falciparum in Africa. N Engl J Med. 2017;377:305–306.
  • Wongsrichanalai C, Pickard AL, Wernsdorfer WH, et al. Epidemiology of drug-resistant malaria. Lancet Infect Dis. 2002;2:209–218.
  • Leang R, Taylor WRJ, Bouth DM, et al. Evidence of Plasmodium falciparum malaria multidrug resistance to artemisinin and piperaquine in Western Cambodia: dihydroartemisinin-piperaquine open-label multicenter clinical assessment. Antimicrob Agents Chemother. 2015;59:4719–4726.
  • Na-Bangchang K, Muhamad P, Ruaengweerayut R, et al. Identification of resistance of Plasmodium falciparum to artesunate-mefloquine combination in an area along the Thai-Myanmar border: integration of clinico-parasitological response, systemic drug exposure, and in vitro parasite sensitivity. Malar J. 2013;12:263.
  • Wellems TE, Plowe CV. Chloroquine-resistant malaria. J Infect Dis. 2001;184:770–776.
  • Harinasuta T, Suntharasamai P, Viravan C. Chloroquine-resistant falciparum malaria in Thailand. Lancet. 1965;2:657–660.
  • Moore DV, Lanier JE. Observations on two Plasmodium Falciparum infections with an abnormal response to chloroquine. Am J Trop Med Hyg. 1961;10:5–9.
  • Young MD, Moore DV. Chloroquine resistance in Plasmodium falciparum. Am J Trop Med Hyg. 1961;10:317–320.
  • Trape JF. The public health impact of chloroquine resistance in Africa. Am J Trop Med Hyg. 2001;64:12–17.
  • Price RN, von Seidlein L, Valecha N, et al. Global extent of chloroquine-resistant Plasmodium vivax: a systematic review and meta-analysis. Lancet Infect Dis. 2014;14:982–991.
  • Ridley RG, Hofheinz W, Matile H, et al. 4-aminoquinoline analogs of chloroquine with shortened side chains retain activity against chloroquine-resistant Plasmodium falciparum. Antimicrob Agents Chemother. 1996;40:1846–1854.
  • De D, Krogstad FM, Cogswell FB, et al. Aminoquinolines that circumvent resistance in Plasmodium falciparum in vitro. Am J Trop Med Hyg. 1996;55:579–583.
  • De D, Krogstad FM, Byers LD, et al. Structure-activity relationships for antiplasmodial activity among 7-substituted 4-aminoquinolines. J Med Chem. 1998;41:4918–4926.
  • WHO. Q&A on artemisinin resistance [Internet]. WHO. [cited 2018 Oct 10]. Available from: http://www.who.int/malaria/media/artemisinin_resistance_qa/en/
  • Leang R, Barrette A, Bouth DM, et al. Efficacy of dihydroartemisinin-piperaquine for treatment of uncomplicated Plasmodium falciparum and Plasmodium vivax in Cambodia, 2008–2010. Antimicrob Agents Chemother. 2013;57:818–826.
  • Saunders DL, Vanachayangkul P, Lon C Dihydroartemisinin–piperaquine failure in Cambodia [Internet]. 2014 [cited 2018 Oct 5]. Available from: https://www.nejm.org/doi/10.1056/NEJMc1403007.
  • Spring MD, Lin JT, Manning JE, et al. Dihydroartemisinin-piperaquine failure associated with a triple mutant including kelch13 C580Y in Cambodia: an observational cohort study. Lancet Infect Dis. 2015;15:683–691.
  • Drugs@FDA: FDA approved drug products [Internet]. [cited 2018 Oct 10]. Available from: https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=BasicSearch.process.
  • Research C for DE and drug approvals and databases - drug trials snapshots: KRINTAFEL [Internet]. [cited 2018 Oct 10]. Available from: https://www.fda.gov/Drugs/InformationOnDrugs/ucm615729.htm.
  • Medicines for Malaria Venture. Developing antimalarials to save lives [Internet]. [cited 2018 Oct 10]. Available from: https://www.mmv.org/.
  • Burrows JN, Duparc S, Gutteridge WE, et al. New developments in anti-malarial target candidate and product profiles. Malar J. 2017;16:26.
  • Isba R, Zani B, Gathu M, et al. Artemisinin-naphthoquine for treating uncomplicated Plasmodium falciparum malaria. Cochrane Database Syst Rev. 2015;2015(2):Article No. CD011547.
  • Kreidenweiss A, Kremsner PG, Dietz K, et al. In vitro activity of ferroquine (SAR97193) is independent of chloroquine resistance in Plasmodium falciparum. Am J Trop Med Hyg. 2006;75:1178–1181.
  • Moehrle JJ, Duparc S, Siethoff C, et al. First-in-man safety and pharmacokinetics of synthetic ozonide OZ439 demonstrates an improved exposure profile relative to other peroxide antimalarials. Br J Clin Pharmacol. 2013;75:524–537.
  • Ehrlich P, Guttmann P. Ueber die Wirkung des Methylenblau bei Malaria. Berlin Klin Woch. 1891;28:953–956.
  • Mombo-Ngoma G, Remppis J, Sievers M, et al. Efficacy and safety of fosmidomycin-piperaquine as nonartemisinin-based combination therapy for uncomplicated falciparum malaria: a single-arm, age de-escalation proof-of-concept study in Gabon. Clin Infect Dis. 2018;66:1823–1830.
  • Fernandes JF, Lell B, Agnandji ST, et al. Fosmidomycin as an antimalarial drug: a meta-analysis of clinical trials. Future Microbiol. 2015;10:1375–1390.
  • MMV-Supported Projects. Medicines for malaria venture [Internet]. [cited 2018 Oct 15]. Available from: https://www.mmv.org/research-development/mmv-supported-projects.
  • Fidock DA, Nomura T, Talley AK, et al. Mutations in the P. falciparum digestive vacuole transmembrane protein PfCRT and evidence for their role in chloroquine resistance. Mol Cell. 2000;6:861–871.
  • Sidhu ABS, Verdier-Pinard D, Fidock DA. Chloroquine resistance in Plasmodium falciparum malaria parasites conferred by pfcrt mutations. Science. 2002;298:210–213.
  • Pubchem. AQ-13 Free base [Internet]. [cited 2018 Oct 9]. Available from: https://pubchem.ncbi.nlm.nih.gov/compound/3805581.
  • Hocart SJ, Liu H, Deng H, et al. 4-aminoquinolines active against chloroquine-resistant Plasmodium falciparum: basis of antiparasite activity and quantitative structure-activity relationship analyses. Antimicrob Agents Chemother. 2011;55:2233–2244.
  • Ramanathan-Girish S, Catz P, Creek MR, et al. Pharmacokinetics of the antimalarial drug, AQ-13, in rats and cynomolgus macaques. Int J Toxicol. 2004;23:179–189.
  • Mzayek F, Deng H, Mather FJ, et al. Randomized dose-ranging controlled trial of AQ-13, a candidate antimalarial, and chloroquine in healthy volunteers. PLoS Clin Trials. 2007;2:e6.
  • Koita OA, Sangaré L, Miller HD, et al. AQ-13, an investigational antimalarial, versus artemether plus lumefantrine for the treatment of uncomplicated Plasmodium falciparum malaria: a randomised, phase 2, non-inferiority clinical trial. Lancet Infect Dis. 2017;17:1266–1275.
  • Ducharme J, Farinotti R. Clinical pharmacokinetics and metabolism of chloroquine. Focus on Recent Advancements. Clin Pharmacokinet. 1996;31:257–274.
  • Projean D, Baune B, Farinotti R, et al. In vitro metabolism of chloroquine: identification of CYP2C8, CYP3A4, and CYP2D6 as the main isoforms catalyzing N-desethylchloroquine formation. Drug Metab Dispos. 2003;31:748–754.
  • Riccio ES, Lee PS, Winegar RA, et al. Genetic toxicology testing of the antimalarial drugs chloroquine and a new analog, AQ-13. Environ Mol Mutagen. 2001;38:69–79.
  • Riou B, Barriot P, Rimailho A, et al. Treatment of severe chloroquine poisoning. N Engl J Med. 1988;318:1–6.
  • Bustos MD, Gay F, Diquet B, et al. The pharmacokinetics and electrocardiographic effects of chloroquine in healthy subjects. Trop Med Parasitol. 1994;45:83–86.
  • Holmgren G, Gil JP, Ferreira PM, et al. Amodiaquine resistant Plasmodium falciparum malaria in vivo is associated with selection of pfcrt 76T and pfmdr1 86Y. Infect Genet Evol. 2006;6:309–314.
  • Held J, Jeyaraj S, Kreidenweiss A. Antimalarial compounds in Phase II clinical development. Expert Opin Investig Drugs. 2015;24:363–382.
  • Berliner RW, Earle DP, Taggart JV, et al. Studies on the chemotherapy of the human malarias. VI. The physiological disposition, antimalarial activity, and toxicity of several derivatives of 4-aminoquinoline. J Clin Invest. 1948;27:98–107.

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.